Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
India
/
Pharmaceuticals & Biotech
/
Tarsons Products
TARSONS
Tarsons Products
Rising Sustainability Pressures And Tariffs Will Crush Profitability
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
01 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
₹347.00
8.5% undervalued
intrinsic discount
16 Aug
₹317.45
1Y
-29.9%
7D
-6.3%
Loading
1Y
-29.9%
7D
-6.3%
Author's Valuation
₹347.0
8.5% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
₹347.0
8.5% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
6b
2019
2021
2023
2025
2027
2028
Revenue ₹6.1b
Earnings ₹1.1b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
14.01%
Life Sciences revenue growth rate
0.33%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
13.88%
Calculation
₹1.11b
Earnings '28
x
22.53x
PE Ratio '28
=
₹25.08b
Market Cap '28
₹25.08b
Market Cap '28
/
49.26m
No. shares '28
=
₹509.08
Share Price '28
₹509.08
Share Price '28
Discounted to 2025 @ 13.83% p.a.
=
₹345.17
Fair Value '25
